BIOVF:OTC-Swedish Orphan Biovitrum AB (publ) (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 19.43

Change

-0.60 (-3.00)%

Market Cap

USD 5.88B

Volume

200.00

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases. The company offers Alprolix for haemophilia B; Doptelet for chemotherapy induced thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. It also develops drug substance for ReFacto AF; BIVV001 for haemophilia A; BIVV0023 for haemophilia B; and Nirsevimab for respiratory syncytial virus. The company operates in Europe, North America, the Middle East, Russia, North Africa, and Asia. It has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-25 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKKGY MERCK Kommanditgesellschaft au..

+0.40 (+1.16%)

USD74.62B 33.16 18.04
MKGAF MERCK Kommanditgesellschaft au..

-1.38 (-0.80%)

USD74.62B 33.37 18.04
TKPHF Takeda Pharmaceutical Company ..

+0.40 (+1.09%)

USD54.17B 22.33 0.12
ESALF Eisai Co., Ltd

N/A

USD21.13B 32.20 0.12
ESALY Eisai Co., Ltd

+2.01 (+2.72%)

USD21.13B 35.45 0.12
SFOSF Shanghai Fosun Pharmaceutical ..

+0.08 (+1.67%)

USD18.79B 28.40 3.62
SGIOY Shionogi & Co., Ltd

+0.24 (+1.76%)

USD16.76B 2.07 0.08
SGIOF Shionogi & Co., Ltd

+0.75 (+1.36%)

USD16.76B 16.65 0.08
TEVJF Teva Pharmaceutical Industries..

+0.50 (+4.17%)

USD13.07B 900.00 16.02
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

USD10.43B 79.00 0.21

ETFs Containing BIOVF

Symbol Name Weight Mer Price(Change) Market Cap
BIGT:LSE L&G Pharma Breakthrou.. 0.00 % 0.75 %

+7.95 (+0.81%)

USD0.02B
ETLI:F L&G Pharma Breakthrou.. 0.00 % 0.75 %

+0.11 (+1.01%)

USD0.03B
EXSE:F iShares STOXX Europe Smal.. 0.00 % 0.20 %

-0.52 (-1.57%)

USD0.39B
ETLI:XETRA L&G Pharma Breakthrou.. 0.00 % 0.75 %

+0.14 (+1.29%)

USD0.03B
EXSE:XETRA iShares STOXX Europe Smal.. 0.00 % 0.20 %

-0.40 (-1.22%)

USD0.46B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.61% 19% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.61% 19% F 30% F
Trailing 12 Months  
Capital Gain 7.05% 46% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.05% 46% F 47% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 3.83% 49% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.83% 47% F 45% F
Risk Return Profile  
Volatility (Standard Deviation) 23.59% 94% A 68% D+
Risk Adjusted Return 16.23% 60% D- 49% F
Market Capitalization 5.88B 94% A 84% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 14.75 41% F 49% F
Price/Book Ratio 2.62 45% F 39% F
Price / Cash Flow Ratio 1.62 14% F 36% F
EV/EBITDA 1.14 64% D 64% D
Management Effectiveness  
Return on Equity 18.00% 94% A 88% B+
Return on Invested Capital 16.89% 79% C+ 80% B-
Return on Assets 7.89% 93% A 92% A-
Debt to Equity Ratio 95.34% 10% F 20% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.90 55% F 50% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.